PeptiSystems
New generation of instruments for solid-phase synthesis production of peptide and oligonucleotide therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | €3.9m | Late VC | |
| Total Funding | 000k | ||
| SEK | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 60 % | - | - | - | 6285 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 71 % | (520 %) | - | - | (1903 %) | 27 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Founded in 2014, PeptiSystems specializes in the research, development, manufacturing, and supply of cutting-edge instruments for the biopharmaceutical and biotech industries. The company's core focus is on solid phase synthesis production of peptide and oligonucleotide therapeutics. PeptiSystems' instruments are designed for both process development and large-scale synthesis, utilizing advanced flowthrough column technology. Their flagship product, PeptiPilot, is a compact, pump-driven system that offers flexible, cost-efficient, and fully automated small-scale synthesis and process development. The unique linear scale-up technology ensures that synthesis parameters remain consistent from small-scale to large-scale manufacturing, optimizing time and efficiency. PeptiSystems generates revenue by selling these specialized instruments to biopharmaceutical and biotech companies engaged in therapeutic development. The market they operate in is highly specialized, catering to clients who require precise and reliable synthesis tools for their research and production needs.
Keywords: peptide synthesis, oligonucleotide synthesis, biopharmaceutical, biotech, solid phase synthesis, flowthrough column technology, process development, large-scale production, automated systems, linear scale-up.